Prognostic and functional importance of the engraftment-associated genes in the patient-derived xenograft models of triple-negative breast cancers

Breast Cancer Research and Treatment

Volumn 154, Issue 1, 2015, Pages 13-22

  Moon, Hyeong Gon ^a   Oh, Keunhee ^a   Lee, Jiwoo ^a   Lee, Minju ^a   Kim, Ju Yeon ^b   Yoo, Tae Kyung ^a   Seo, Myung Won ^a   Park, Ae Kyung ^c   Ryu, Han Suk ^d   Jung, Eun Jung ^b   Kim, Namshin ^e   Jeong, Seongmun ^e   Han, Wonshik ^a   Lee, Dong Sup ^a   Noh, Dong Young ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Gyeongsang National University   (South Korea)

^c Sunchon National University   (South Korea)

^d Seoul National University Hospital   (South Korea)

^e Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

Breast cancer; Engraftment; Patient derived xenograft; Prognosis; Triple negative breast cancer

Indexed keywords

TRANSKETOLASE; COLLAGEN PROLYL-4-HYDROXYLASE ALPHA SUBUNIT 2, HUMAN; NUCLEAR PROTEIN; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; TSSC3 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CELL INVASION; CELL PROLIFERATION; CLINICAL FEATURE; CONTROLLED STUDY; DOWN REGULATION; ENGRAFTMENT; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE FUNCTION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; P4HA2 GENE; PHLDA2 GENE; PRIORITY JOURNAL; SURVIVAL PREDICTION; SURVIVAL RATE; TKT GENE; TRIPLE NEGATIVE BREAST CANCER; TUMOR ENGRAFTMENT; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; ANIMAL; BIOSYNTHESIS; DRUG SCREENING; FEMALE; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; PROGNOSIS; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; NUCLEAR PROTEINS; PROGNOSIS; PROLYL HYDROXYLASES; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84945476387     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-015-3585-y     Document Type: Article

References (22)

1. Criscitiello C, Azim HA Jr, Schouten PC, Linn SC, Sotiriou C (2012) Understanding the biology of triple-negative breast cancer. Ann Oncol 23(Suppl 6):vi13–vi18. doi:10.1093/annonc/mds188
2. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121(7):2750–2767. doi:10.1172/JCI45014
3. Burstein MD, Tsimelzon A, Poage GM, Covington KR, Contreras A, Fuqua SA, Savage MI, Osborne CK, Hilsenbeck SG, Chang JC, Mills GB, Lau CC, Brown PH (2015) Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res 21(7):1688–1698. doi:10.1158/1078-0432.CCR-14-0432
4. Desmedt C, Haibe-Kains B, Wirapati P, Buyse M, Larsimont D, Bontempi G, Delorenzi M, Piccart M, Sotiriou C (2008) Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 14(16):5158–5165. doi:10.1158/1078-0432.CCR-07-4756
5. Hidalgo M, Amant F, Biankin AV, Budinska E, Byrne AT, Caldas C, Clarke RB, de Jong S, Jonkers J, Maelandsmo GM, Roman-Roman S, Seoane J, Trusolino L, Villanueva A (2014) Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov 4(9):998–1013. doi:10.1158/2159-8290.CD-14-0001
6. Landis MD, Lehmann BD, Pietenpol JA, Chang JC (2013) Patient-derived breast tumor xenografts facilitating personalized cancer therapy. Breast Cancer Res 15(1):201. doi:10.1186/bcr3355
7. Siolas D, Hannon GJ (2013) Patient-derived tumor xenografts: transforming clinical samples into mouse models. Cancer Res 73(17):5315–5319. doi:10.1158/0008-5472.CAN-13-1069
8. Kabos P, Finlay-Schultz J, Li C, Kline E, Finlayson C, Wisell J, Manuel CA, Edgerton SM, Harrell JC, Elias A, Sartorius CA (2012) Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures. Breast Cancer Res Treat 135(2):415–432. doi:10.1007/s10549-012-2164-8
9. Li S, Shen D, Shao J, Crowder R, Liu W, Prat A, He X, Liu S, Hoog J, Lu C, Ding L, Griffith OL, Miller C, Larson D, Fulton RS, Harrison M, Mooney T, McMichael JF, Luo J, Tao Y, Goncalves R, Schlosberg C, Hiken JF, Saied L, Sanchez C, Giuntoli T, Bumb C, Cooper C, Kitchens RT, Lin A, Phommaly C, Davies SR, Zhang J, Kavuri MS, McEachern D, Dong YY, Ma C, Pluard T, Naughton M, Bose R, Suresh R, McDowell R, Michel L, Aft R, Gillanders W, DeSchryver K, Wilson RK, Wang S, Mills GB, Gonzalez-Angulo A, Edwards JR, Maher C, Perou CM, Mardis ER, Ellis MJ (2013) Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep 4(6):1116–1130. doi:10.1016/j.celrep.2013.08.022
10. Marangoni E, Vincent-Salomon A, Auger N, Degeorges A, Assayag F, de Cremoux P, de Plater L, Guyader C, De Pinieux G, Judde JG, Rebucci M, Tran-Perennou C, Sastre-Garau X, Sigal-Zafrani B, Delattre O, Dieras V, Poupon MF (2007) A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin Cancer Res 13(13):3989–3998. doi:10.1158/1078-0432.CCR-07-0078
11. Ding L, Ellis MJ, Li S, Larson DE, Chen K, Wallis JW, Harris CC, McLellan MD, Fulton RS, Fulton LL, Abbott RM, Hoog J, Dooling DJ, Koboldt DC, Schmidt H, Kalicki J, Zhang Q, Chen L, Lin L, Wendl MC, McMichael JF, Magrini VJ, Cook L, McGrath SD, Vickery TL, Appelbaum E, Deschryver K, Davies S, Guintoli T, Lin L, Crowder R, Tao Y, Snider JE, Smith SM, Dukes AF, Sanderson GE, Pohl CS, Delehaunty KD, Fronick CC, Pape KA, Reed JS, Robinson JS, Hodges JS, Schierding W, Dees ND, Shen D, Locke DP, Wiechert ME, Eldred JM, Peck JB, Oberkfell BJ, Lolofie JT, Du F, Hawkins AE, O’Laughlin MD, Bernard KE, Cunningham M, Elliott G, Mason MD, Thompson DM Jr, Ivanovich JL, Goodfellow PJ, Perou CM, Weinstock GM, Aft R, Watson M, Ley TJ, Wilson RK, Mardis ER (2010) Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464(7291):999–1005. doi:10.1038/nature08989
12. Moon HG, Han W, Ahn SK, Cho N, Moon WK, Im SA, Park IA, Noh DY (2013) Breast cancer molecular phenotype and the use of HER2-targeted agents influence the accuracy of breast MRI after neoadjuvant chemotherapy. Ann Surg 257(1):133–137. doi:10.1097/SLA.0b013e3182686bd9
13. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM (2007) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13(8):2329–2334. doi:10.1158/1078-0432.CCR-06-1109
14. Madden SF, Clarke C, Gaule P, Aherne ST, O’Donovan N, Clynes M, Crown J, Gallagher WM (2013) BreastMark: an integrated approach to mining publicly available transcriptomic datasets relating to breast cancer outcome. Breast Cancer Res 15(4):R52. doi:10.1186/bcr3444
15. Petrillo LA, Wolf DM, Kapoun AM, Wang NJ, Barczak A, Xiao Y, Korkaya H, Baehner F, Lewicki J, Wicha M, Park JW, Spellman PT, Gray JW, van’t Veer L, Esserman LJ (2012) Xenografts faithfully recapitulate breast cancer-specific gene expression patterns of parent primary breast tumors. Breast Cancer Res Treat 135(3):913–922. doi:10.1007/s10549-012-2226-y
16. Zhang X, Claerhout S, Prat A, Dobrolecki LE, Petrovic I, Lai Q, Landis MD, Wiechmann L, Schiff R, Giuliano M, Wong H, Fuqua SW, Contreras A, Gutierrez C, Huang J, Mao S, Pavlick AC, Froehlich AM, Wu MF, Tsimelzon A, Hilsenbeck SG, Chen ES, Zuloaga P, Shaw CA, Rimawi MF, Perou CM, Mills GB, Chang JC, Lewis MT (2013) A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res 73(15):4885–4897. doi:10.1158/0008-5472.CAN-12-4081
17. DeRose YS, Wang G, Lin YC, Bernard PS, Buys SS, Ebbert MT, Factor R, Matsen C, Milash BA, Nelson E, Neumayer L, Randall RL, Stijleman IJ, Welm BE, Welm AL (2011) Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med 17(11):1514–1520. doi:10.1038/nm.2454
18. Visonneau S, Cesano A, Torosian MH, Miller EJ, Santoli D (1998) Growth characteristics and metastatic properties of human breast cancer xenografts in immunodeficient mice. Am J Pathol 152(5):1299–1311
19. Burstein MD, Tsimelzon A, Poage GM, Covington KR, Contreras A, Fuqua S, Savage M, Osborne CK, Hilsenbeck SG, Chang JC, Mills GB, Lau CC, Brown PH (2014) Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res. doi:10.1158/1078-0432.CCR-14-0432
20. Rody A, Karn T, Liedtke C, Pusztai L, Ruckhaeberle E, Hanker L, Gaetje R, Solbach C, Ahr A, Metzler D, Schmidt M, Muller V, Holtrich U, Kaufmann M (2011) A clinically relevant gene signature in triple negative and basal-like breast cancer. Breast Cancer Res 13(5):R97. doi:10.1186/bcr3035
21. Gajewski TF, Schreiber H, Fu YX (2013) Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 14(10):1014–1022. doi:10.1038/ni.2703
22. Xiong G, Deng L, Zhu J, Rychahou PG, Xu R (2014) Prolyl-4-hydroxylase alpha subunit 2 promotes breast cancer progression and metastasis by regulating collagen deposition. BMC Cancer 14:1. doi:10.1186/1471-2407-14-1